A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned

Vaccine

Volumn 31, Issue 15, 2013, Pages 1970-1974

  Szu, Shousun C ^a   Hunt, Steven ^a   Xie, Guilin ^b   Robbins, John B ^a   Schneerson, Rachel ^a   Gupta, Rajesh K ^c   Zhao, Zhigang ^b   Tan, Xiaomei ^b  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b LANZHOU INSTITUTE OF BIOLOGICAL PRODUCTS   (China)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Antibody; Capsule; Reference; Serum; Standard; Typhoid; Vi

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; TYPHOID VACCINE; UNCLASSIFIED DRUG; VI ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION; PSEUDOMONAS AERUGINOSA; SALMONELLA TYPHI; TYPHOID FEVER;

ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; CHILD, PRESCHOOL; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN G; POLYSACCHARIDES, BACTERIAL; PSEUDOMONAS AERUGINOSA; REFERENCE STANDARDS; SALMONELLA TYPHI; TYPHOID FEVER; VACCINES, CONJUGATE;

EID: 84875237913     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.02.006     Document Type: Article

References (38)

1. Crump J.A., Luby S.P., Mintz E.D. The global burden of typhoid fever. Bull World Health Organ 2004, 50:346-353.
2. Ochai R.L., Acosia C.J., Danovaro-Holiday M.C., Baiqing D., Bhattacharfya S.K., Agini M.D., et al. A study of typhoid fever in five Asian countries: disease burden and implications for control. Bull WHO 2008, 86:260-268.
3. Parry C.M., Ho V.A., Phuong le T., Bay P.V., Lanh M.N., Tung le T., et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother 2007, 51:819-825.
4. Sinha A., Sazawal S., Kumar R., Sood S., Reddaiah V.P., Singh B., et al. Typhoid fever in children ages less than 5 years. Lancet 1999, 354:734-737.
5. Brooks W.A., Hossain A., Goswami D., Nahar K., Alam K., Ahmed N., et al. Bacteremic typhoid fever in children in an urban slum, Bangladesh. Emerg Infect Dis 2005, 11:326-329.
6. Kelly-Hope L.A., Alonso W.J., Thiem V.D., Anh D.D., Canh do G., Lee H., et al. Geographical distribution and risk factors associated with enteric diseases in Vietnam. Am J Trop Med Hyg 2007, 76:706-712.
7. Dutta U., Garg P.K., Kumar R., Tandon R.K. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am J Gastroenterol 2000, 97:784-787.
8. Klugman K.P., Koornhof H.J., Robbins J.B., Le Cam N.N. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996, 14:435-443.
9. Acharya I.L., Lowe C.U., Thapa R., Gurubacharya V.L., Shrestha M.B., Bryla D.A., et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: a preliminary report one year after immunization. N Engl J Med 1987, 317:1101-1104.
10. Yang H.H., Wu C.G., Xie G.Z. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ 2001, 79:625-631.
11. Requirements for Vi polysaccharide typhoid vaccine. World Health Organization Technical Report Series. 1994; No. 840.
12. Khan MI, Soofi SB, Ochiai RL, Habib MA, Sahito SM, Nizami SQ, et al. Effectiveness of Vi capsular polysaccharide typhoid vccine among children: a cluster randomized trial in Karachi, Pakistan. Vaccine 2012 (June 15, in print).
13. Szu S.C., Taylor D.N., Taylor A.C., Trofa J.D., Clements J.D., Shiloach J.C., et al. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect Immun 1994, 62:4440-4444.
14. Kossaczka Z., Lin F-Y., Ho V.A., Thuy N.T.T., Bay P.V., Thanh T.C., et al. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 1999, 67:5806-5810.
15. Lin F-Y.C., Ho V.A., Khiem H.B., Trach D.D., Bay P.V., Thanh T.C., et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001, 344:1263-1269.
16. Lanh M.N., Bay P.V., Ho V.A., Thanh T.C., Lin F-Y.C., Bryla D.A., et al. Persistent efficacy of Vi conjugates against typhoid fever in young children. N Engl J Med 2003, 349:1390-1391.
17. Thiem V.D., Lin F-Y.C., Canh D.G., Son N.H., Anh D.D., Mao D., et al. The Vi conjugate typhoid vaccine is safe, elicites protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol 2011, 18:730-735.
18. van Damme P., Kafeja F., Anemona A., Basile V., Hilbert A.K., De Coster I., et al. Safety, immunogenicity and dose ranging of a new Vi-CRM conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults. PLoS ONE 2011, 6:e25398.
19. Micoli F., Rondini S., Pisoni I., Proietti D., Berti F., Costantino P., et al. Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine 2011, 29:712-720.
20. Cui C.F., Carbis R., An S.J., Jang H., Czerkinsky C., Szu S.C., et al. The physical chemical characterization and immunologic properties of Salmonella ser. Typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin Vaccine Immunol 2010, 17:73-79.
21. Guide book on immunization, Individual Vaccines. Indian Academy of Pediatrics Vaccine. 2009; Chapter 11, pp. 56-8.
22. Ferry B.L., Misbah S.A., Stephens P., Sherrell Z., lythgoe H., Bateman E., et al. Development of an anti-Salmonella typhi Vi ELISA: assessment of immunocompetence in healthy donors. Clin Exp Immunol 2004, 136:297-303.
23. Pulickal A.S., Gautam S., Clutterbuck E.A., Thorson S., Basynat B., Adhikari N., et al. Kinetics of the natural, humoral immune response to Salmonella enterica serovar typhi in Kathmandu, Nepal. Clin Vaccine Immunol 2009, 16:1413-1419.
24. Staats H.F., Kirwan S.M., Whisnant C.C., Stephenson J.L., Wagener D.K., Majumder P.P. Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide. Clin Vaccine Immunol 2010, 17:412-419.
25. Gotschlich E.C., Rey M., Triau R., Sparks K.J. Quantitative determination of the human immune response to immunization with meningococcal vaccines. J Clin Invest 1972, 51:89-96.
26. Robbins J.B., Whisnant J.K., Schneerson R., Parke J.C. Quantitative measurement of the " natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res 1973, 7:103-110.
27. Quataert S.A., Rittenhouse-Olson K., Kirch C.S., Hu B., Secor S., Stong N., et al. Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, Lot 89-S(F). Clin Diagn Lab Immunol 2004, 11:1064-1069.
28. Holder P.K., Maslanka S.E., Pais L.B., Dykes J., Plikaytis B.D., Carlone G.M. Assignment of Neisseria meningitides serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC1992. Clin Diagn Lab Immunol 1995, 2:132-137.
29. Epstein J.S. Alternative strategies in assuring blood safety: an overview. Biologicals 2010, 38:31-35.
30. Harkins K.R. Antibody purification methods. Basic Methods in Antibody Production and Characterization 2000, CRC Press, Boca Raton, FL, pp. 141-66. G.C. Howard, D.R. Bethell (Eds.).
31. Steinbuch M., Audran R. The isolation of IgG from mammalian sera with the aid of caprylic acid. Arch Biochem Biophys 1969, 134:279-284.
32. Kabat and Mayer Experimental Immunochemistry. 2nd ed., Charles C. Thomas, Springfield, IL; 1971. p. 72-5.
33. Brown R., Jarvis K.L., Hyland K.J. Protein measurement using bicinchoninic acid: elimination of interfering substances. Anal Biochem 1989, 180:136-139.
34. Plikaytis B.D., Goldblatt D., Frasch C.E., Blondeau C., Bybel M.J., Giebink G.S., et al. An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J Clin Microbiol 2000, 38:2043-2050.
35. Gupta A., My Thanh N.T., Olsen S.J., Sivapalasingam S., My Trinh T.T., Phuong Lan N.T., et al. Evaluation of community-based serologic screening for identification of chronic Salmonella typhi carriers in Vietnam. Int J Infect Dis 2006, 10:309-314.
36. Lanata C.F., Ristora C., Jimeniez L., Garcia G., Levine M.W., Black R.E., et al. Vi serology in detection of chronic Salmonella typhi carriers in an endemic area. Lancet 1983, 1:441-442.
37. Engleberg N.C., Barrett T.J., Fisher H., Porter B., Hurtado E., Hughes J.W. Identification of a carrier by using Vi enzyme-linked immunosorbent assay serology in an outbreak of typhoid fever on an Indian reservation. J Clin Microbiol 1983, 18:1320-1322.
38. Saha S.K., Baqui A.H., Hanif M., Darmstadt G.L., Ruhulamin M., Nagatake T., et al. Typhoid fever in Bangladesh: implications for vaccination policy. Pediatr Infect Dis J 2001, 20:521-524.